AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27192132
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of 6.8 g/kg‐1 of room temperature (22.3°C) sports drink (CON)
Trial: 22688312
Drug: Clopidogrel 300
RxNorm normalized name: clopidogrel 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 300 mg loading dose followed by 75 mg maintenance dose
Trial: 22688312
Drug: Ticlopidine 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine 100 mg twice daily
Trial: 12684609
Drug: Amisulpride (400-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (400-800 mg/day)
Trial: 8831181
Drug: Nifedipine SR
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine SR 20 mg b.i.d.
Trial: 8831181
Drug: Metoprolol (OROS)
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol (OROS) 14/190 mg o.d.
Trial: 8831181
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metoprolol and nifedipine
Trial: 1336463
Drug: lisinopril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril (20 mg/40 mg o.d.)
Trial: 1336463
Drug: atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol (50 mg/100 mg o.d.)
Trial: 4016825
Drug: Naloxone (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.8 mg bolus, intravenous)
Trial: 31060838
Drug: Standard enteral
RxNorm normalized name: Standard enteral formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard enteral nutrition (14.1 g/100 mL carbohydrate)
Trial: 31060838
Drug: Intervention enteral
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention enteral nutrition (7.4 g/100 mL carbohydrate)
Trial: 29047161
Drug: Prophylactic donor
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic donor lymphocyte infusion (DLI)
Trial: 24582316
Drug: GSK679586 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK679586 (10 mg/kg, once-monthly intravenous infusions)
Trial: 22158915
Drug: Pseudoephedrine (PSE)
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine (PSE) 2.5 mg/kg
Trial: 19880909
Drug: Inhaled mannitol
RxNorm normalized name: mannitol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled mannitol 420 mg bid for 2 weeks
Trial: 8374246
Drug: Intravenous zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous zinc supplementation for 2 months
Trial: 3946944
Drug: Ophthalmic timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic timolol (0.5%)
Trial: 18501861
Drug: Prenatal drug
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal drug exposure (PDE) group
Trial: 18501861
Drug: Non-drug-exposed children
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-drug-exposed children (control group)
Trial: 15804071
Drug: Sibutramine 10
RxNorm normalized name: sibutramine 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 10 mg/day for 12 weeks
Trial: 15804071
Drug: Placebo tablet/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet/day for 12 weeks
Trial: 27138022
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of VGX-1027 (1-800 mg)
Trial: 27138022
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of VGX-1027 (40-400 mg)
Trial: 27138022
Drug: Pharmacokinetics of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetics of VGX-1027
Trial: 27138022
Drug: Drug accumulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug accumulation
Trial: 27138022
Drug: Excretion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excretion of VGX-1027
Trial: 12019482
Drug: Auricularum powder
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricularum powder (dexamethasone 10 mg, oxytetracycline HCl 90,000 U, polymyxin B Sulfate 100,000 U, nystatin 1,000,000 U)
Trial: 12019482
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Auricularum powder, Ciprofloxacin, Tobramycin)
Trial: 9786607
Drug: Cilnidipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilnidipine (5 to 20 mg once daily)
Trial: 9786607
Drug: Nisoldipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (5 to 20 mg once daily)
Trial: 7941918
Drug: Diltiazem 300
RxNorm normalized name: diltiazem 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 300 mg od
Trial: 7941918
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg bd
Trial: 7941918
Drug: Bendrofluazide 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide 5 mg od
Trial: 2960271
Drug: Placebo transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo transdermal therapeutic system
Trial: 2960271
Drug: Silver-patch test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver-patch test
Trial: 29145543
Drug: Ipilimumab, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab, 10 mg/kg, every 21 days for 4 cycles followed by 4 cycles of maintenance therapy every 12 weeks
Trial: 29145543
Drug: Ipilimumab, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab, 3 mg/kg, every 21 days for 4 cycles (run-in safety cohort)
Trial: 29145543
Drug: Ipilimumab (overall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (overall treatment)
Trial: 21077506
Drug: 3.9 mg
RxNorm normalized name: menthol 3.9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.9 mg transdermal 17beta‐estradiol patch
Trial: 16004014
Drug: Botox injections
RxNorm normalized name: Botox
DrugBank: DaxibotulinumtoxinA (DB17929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botox injections into one half of the chin
Trial: 16004014
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) injections into the other half of the chin
Trial: 12857521
Drug: Shen-Fu (SF)
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shen-Fu (SF) injection (0.5 ml/kg at the beginning of surgery, followed by continuous infusion of 100 ml SF (1.0 ml/kg) diluted in saline at 0.004 ml x Kg(‐1) x min(‐1))
Trial: 12857521
Drug: Shen-Fu (SF)
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shen-Fu (SF) injection
Trial: 8948561
Drug: Daily screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily screening of respiratory function followed by two-hour trials of spontaneous breathing in appropriate patients.
Trial: 8948561
Drug: Daily screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily screening without further intervention (control group).
Trial: 2008181
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of pentamidine isethionate every 28 days by inhaler
Trial: 2008181
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of sodium isethionate every 28 days by inhaler (placebo)
Trial: 20031347
Drug: 5-hydroxytryptophan (5-HTP)
RxNorm normalized name: 5-hydroxytryptophan (5-HTP) 50 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-hydroxytryptophan (5-HTP) 150 mg/day
Trial: 18661495
Drug: Piperacillin-tazobactam (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin-tazobactam (125 mg/kg/day) plus ceftazidime (100 mg/kg/day)
Trial: 18661495
Drug: Cefozopran (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefozopran (100 mg/kg/day)
Trial: 15721732
Drug: Promethazine 6.25
RxNorm normalized name: DM 15/PROMETHAZINE 6.25MG/5ML SYRUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine 6.25 to 25 mg
Trial: 15721732
Drug: Dimenhydrinate 25
RxNorm normalized name: dimenhydrinate 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimenhydrinate 25 to 50 mg
Trial: 15721732
Drug: Droperidol 0.625
RxNorm normalized name: droPERidol 0.625 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 0.625 to 1.25 mg
Trial: 10836660
Drug: Ethinylestradiol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinylestradiol (30 g) and drospirenone (3 mg)
Trial: 10836660
Drug: Ethinylestradiol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinylestradiol (30 g) and desogestrel (150 g)
Trial: 9060547
Drug: Docetaxel 100
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 100 mg/m2 plus cisplatin 75 mg/m2
Trial: 9060547
Drug: Docetaxel 85
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 85 mg/m2 plus cisplatin 100 mg/m2
Trial: 23278775
Drug: Thrice-weekly regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly regimen of antitubercular drugs (2H(3)R(3)Z(3)E(3)/4H(3)R(3)) for 6 months
Trial: 10531771
Drug: Buscopan compositum
RxNorm normalized name: Buscopan
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buscopan compositum (hyoscine butylbromide 20 mg and dipyrone 2.5 g) i.v.
Trial: 9004342
Drug: Clonidine (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.15 mg)
Trial: 2792671
Drug: Acid protection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid protection (antacids, cimetidine, and sucralfate)
Trial: 29271052
Drug: Topical hemostatic
RxNorm normalized name: ferric sulfate 21 % Topical Hemostatic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical hemostatic sealant
Trial: 24734241
Drug: lidocaine+lornoxicam+transdermal nitroglycerine
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidocaine+lornoxicam+transdermal nitroglycerine (group LL-N)
Trial: 24734241
Drug: lidocaine (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidocaine (group L)
Trial: 18322928
Drug: Encouraged to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encouraged to regulate their daily routines
Trial: 1965077
Drug: Formalized inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formalized inactivated hepatitis A vaccine (180, 360, and 720 ELISA units)
Trial: 1965077
Drug: Formalized inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formalized inactivated hepatitis A vaccine
Trial: 382914
Drug: Diazepam (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.4 mg/kg) + Ketamine (2 mg/kg) + Nitrous oxide (50%)
Trial: 382914
Drug: Morphine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (3 mg/kg) + Nitrous oxide (50%)
Trial: 6847465
Drug: Conjunctival irrigation
RxNorm normalized name: Sus scrofa conjunctiva preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjunctival irrigation with saline solution
Trial: 29352714
Drug: Single-agent prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-agent prednisone
Trial: 26544097
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (paclitaxel 200 mg/m² and carboplatin AUC5) and external beam radiotherapy (60 Gy/30 fractions/6 weeks)
Trial: 26544097
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (paclitaxel 200 mg/m² and carboplatin AUC5) followed by external beam radiotherapy (48 Gy/20 fractions/4 weeks) with concomitant cisplatin 30 mg/m² weekly
Trial: 17626040
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) at a dose of 1 g twice daily
Trial: 9618125
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss intervention (6279 kJ/week of physical activity, 33,258-41,462 kJ/week diet and weekly meetings)
Trial: 7653978
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir 800 mg five times per day for seven days (Group A)
Trial: 7653978
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir 800 mg five times per day for seven days (Group B)
Trial: 7653978
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir (both Group A and Group B)
Trial: 31999469
Drug: Ultrasound-guided fascia
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided fascia iliaca block with 50 to 60 mL of 0.35% ropivacaine
Trial: 31999469
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of 20 mL of 0.5% ropivacaine
Trial: 27689343
Drug: High-polyphenol orange
RxNorm normalized name: Orange
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-polyphenol orange juice (HPJ) (745 mg/L)
Trial: 27689343
Drug: Normal-polyphenol orange
RxNorm normalized name: Orange
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-polyphenol orange juice (NPJ) (299 mg/L)
Trial: 10850521
Drug: Gatifloxacin 200
RxNorm normalized name: gatifloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin 200 mg (10 mg/ml)
Trial: 10850521
Drug: Gatifloxacin 200
RxNorm normalized name: gatifloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin 200 mg (1 mg/ml)
Trial: 10850521
Drug: Gatifloxacin 400
RxNorm normalized name: gatifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin 400 mg (2 mg/ml)
Trial: 10850521
Drug: Gatifloxacin 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin 600 mg (2 mg/ml)
Trial: 10850521
Drug: Gatifloxacin 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin 800 mg (2 mg/ml)
Trial: 10850521
Drug: Gatifloxacin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin (all doses)
Trial: 8834289
Drug: Current modes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current modes of prophylaxis and treatment for heterotopic ossification
Trial: 3911961
Drug: Suprofen 5
RxNorm normalized name: Suprofen
DrugBank: Suprofen (DB00870)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suprofen 5 mg/kg
Trial: 3911961
Drug: Suprofen 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprofen 7.5 mg/kg
Trial: 3911961
Drug: Suprofen 10
RxNorm normalized name: suprofen 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprofen 10 mg/kg
Trial: 3911961
Drug: Suprofen 1
RxNorm normalized name: suprofen 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprofen 1 mg/kg
Trial: 3911961
Drug: Suprofen lower
RxNorm normalized name: Suprofen
DrugBank: Suprofen (DB00870)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suprofen lower doses (1, 2, 3, 4 mg/kg)
Trial: 3911961
Drug: Suprofen (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprofen (all doses)
Trial: 26202786
Drug: Sevoflurane-dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane-dexmedetomidine (0.5 μg/kg) (Group SD5, n=24)
Trial: 26202786
Drug: Sevoflurane-dexmedetomidine (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane-dexmedetomidine (0.7 μg/kg) (Group SD7, n=25)
Trial: 21078194
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (17 acupuncture points used 3 times a week for 4 weeks)
Trial: 16634340
Drug: Constraint‐induced therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint‐induced therapy (mitt on the less affected hand 90% of waking hours for 12 days) with 2‐3 patients per therapist and 6 h of group training per day.
Trial: 16634340
Drug: Constraint‐induced group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint‐induced group therapy.
Trial: 12741629
Drug: Combivir (lamivudine
RxNorm normalized name: Combivir (lamivudine 150 MG / zidovudine 300 MG) Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combivir (lamivudine 150 mg/zidovudine 300 mg twice daily) + abacavir (300 mg twice daily)
Trial: 12741629
Drug: Combivir (lamivudine
RxNorm normalized name: Combivir (lamivudine 150 MG / zidovudine 300 MG) Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combivir (lamivudine 150 mg/zidovudine 300 mg twice daily) + nelfinavir (750 mg every 8 h)
Trial: 1457694
Drug: DNA-coated granulated
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA-coated granulated synthetic carbons (30 g, perfusion volume 2.5-3.1 L)
Trial: 6725033
Drug: Postural drainage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postural drainage and bronchodilator therapy
Trial: 20377490
Drug: Perianal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perianal lidocaine injection
Trial: 20377490
Drug: Periprostatic lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periprostatic lidocaine injection
Trial: 20377490
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of perianal-intrarectal lidocaine-prilocaine cream
Trial: 14609301
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 1200 mg daily (3 times 400 mg) for 120 days
Trial: 10513096
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (combined distant and local acupoints)
Trial: 3689627
Drug: CGS 14824
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 14824 A (20 mg)
Trial: 3689627
Drug: Nicardipine (cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (cumulative doses of 1.25, 3.75, and 8.75 mg)
Trial: 27466360
Drug: PHE expansion
RxNorm normalized name: Phe
DrugBank: Phenylalanine (DB00120)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PHE expansion rate (0.31 mL/hour, IQR 0.12-0.55)
Trial: 22287402
Drug: Levofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (500 mg o.i.d), amoxicillin (1 g b.i.d) and proton pump inhibitor (b.i.d) for 10 days (Group 1, n=60)
Trial: 22287402
Drug: Levofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (500 mg b.i.d), amoxicillin (1 g b.i.d) and proton pump inhibitor (b.i.d) for 10 days (Group 2, n=50)
Trial: 19361602
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (1.5 microg/kg every 20 days for 3 months) plus oral iron
Trial: 16638740
Drug: Ritonavir (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir (200 mg; 4 doses over 2 days)
Trial: 11585680
Drug: Subcutaneous IL‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IL‐2 alone (n=13)
Trial: 11585680
Drug: Low-dose IFN‐alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose IFN‐alpha alone (n=5)
Trial: 11585680
Drug: High-dose IFN‐alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IFN‐alpha alone (n=10)
Trial: 31169077
Drug: Cessation pharmacotherapy
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cessation pharmacotherapy
Trial: 28719527
Drug: Standard remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard remifentanil administration
Trial: 25760354
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion threshold (hemoglobin level <7.5 g per deciliter)
Trial: 25760354
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion threshold (hemoglobin level <9 g per deciliter)
Trial: 16817839
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg o.d.
Trial: 12799312
Drug: Intravenous C-peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous C-peptide